In part 4 and the conclusion of this Exclusive Interview about the new diabetes classification, Dr. Schwartz highlights what he is looking forward to at the AACE and ADA conferences, particularly the results of the LEADER and GLP-1 studies.

In part 3 of this Exclusive Interview about the new diabetes classification, facilitating the individual use of "evidence-based practice" to individually assess the situation of a specific patient, instead of allowing media supposition about a drug class -- such as SGLT-2s -- to dictate diabetes treatment.

In part 2 of this Exclusive Interview about the new diabetes classification, Dr. Stanley Schwartz explains the necessity of treating beta cell dysfunction even as early as prediabetes, but also needing health organizations to agree on the early use of certain treatments.

In this exclusive interview transcript, Dr. Stanley Schwartz discusses SGLT-2s and evidence-based medicine: the risk of DKA in Type 2 diabetes is just five in 10,000, compared to a benefit of 38% reduction in cardiovascular mortality.

In this exclusive interview transcript, Dr. Stanley Schwartz discusses the proposed new diabetes classification, which seeks to not only just classify but to help in determining what type of treatment might be best for that patient.

In this week's Homerun Slides, the call for patient-centered approach to diabetes therapy that factors in the patient's individual cause of metabolic dysregulation.

In this week's Homerun Slides, precision medicine - matching the right drug to the right patient.

In this week's Homerun Slides, the cardiovascular benefit of the newer diabetes algorithm and treatment process.

In this week's Homerun Slides, debunking the myth that most patients with type 2 will eventually progress to insulin.

In this week's Homerun Slides, the natural history and progression of diabetes.